Private equity firm CapVest Partners has completed its acquisition of a majority stake in Stada Arzneimittel, the German pharmaceutical company, from Bain Capital and Cinven. The deal, initially agreed upon in September 2025, marks a significant shift in ownership for the global healthcare platform that specializes in consumer healthcare, generics, and specialty pharmaceuticals.

Stada has established itself as a major player in the pharmaceutical industry, recently announcing record revenues of €4.3 billion. The company employs close to 12,000 people worldwide, demonstrating its substantial operational scale and global reach. This acquisition represents a strategic move by CapVest to expand its portfolio in the healthcare sector, particularly in the pharmaceutical manufacturing and distribution space.

The transaction underscores the ongoing consolidation in the pharmaceutical industry, where private equity firms are increasingly targeting established healthcare platforms with strong market positions. For Bain Capital and Cinven, the sale provides an exit opportunity after their investment period, while CapVest gains a well-positioned healthcare company with diversified product lines and international operations. The completion of this deal highlights the continued interest in healthcare assets despite market uncertainties, reflecting the sector's defensive characteristics and long-term growth potential.